Another trial involving Bintrafusp alfa, a PD-L1/TGFΒ fusion protein, in ESCC yielded TRAEs in 63.3% of participants, with 23.3% experiencing grade ≥ 3 events [21]. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.